Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00103376
Status:
TERMINATED
Last Update Posted:
2018-11-05
First Post:
2005-02-07
Brief Title:
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
Sponsor:
Medical University of South Carolina
Organization:
Medical University of South Carolina
Study Overview
Official Title:
VELCADE Bortezomib for Injection Therapy for Early Relapsed Prostate Cancer
Status:
TERMINATED
Status Verified Date:
2018-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Low Accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth Androgens can cause the growth of prostate cancer cells Drugs such as goserelin leuprolide flutamide or bicalutamide may stop the adrenal glands from making androgens Giving bortezomib with hormone therapy may kill more tumor cells
PURPOSE This phase II trial is studying how well giving bortezomib with or without hormone therapy works in treating patients with relapsed prostate cancer
PURPOSE This phase II trial is studying how well giving bortezomib with or without hormone therapy works in treating patients with relapsed prostate cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MUSC-HR-11357 | None | None | None |
| MUSC-031218 | None | None | None |